Ep. 305 - FDA's Future; In Vivo CAR T Plays; Psychedelics; CDK2

The Trump administration’s overhaul of FDA is still underway, but the agency has already veered away from its decades-long trajectory in ways that will profoundly reshape medical product development and the lives of U.S. patients. On the latest BioCentury This Week podcast, BioCentury’s analysts assess who the winners and losers are likely to be as FDA changes shape. The analysts discuss a pair of in vivo CAR T companies: Esobiotec, whose story offers a case study in product-focused strategy, and Capstan Therapeutics, whose in vivo CAR T platform for immunological disorders attracted a buyer in Abbvie. The team also analyzes why data from Compass Pathways for psilocybin therapy COMP360 disappointed investors despite hitting the endpoint, and how molecular glues could be the future of selective CDK2 targeting. This episode of BioCentury This Week was sponsored by ICON Biotech. View full story: https://www.biocentury.com/article/656341 #biotech #biopharma #pharma #lifescience #RandD #drugapproval 00:01 - Sponsor Message: ICON Biotech 02:26 - BioCentury Grand Rounds Europe 05:02 - FDA"s Future 15:03 - Psychedelics 22:53 - Esobiotech"s Fast Exit 31:37 - Molecular Glues and CDK2 34:43 - Abbvie"s Capstan Buy To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text